Updated November 11, 2026
C.R. Bard’s PowerPort™ series of vascular access devices or implantable ports are the subject of recent PowerPort injury lawsuits and trials. The lawsuits allege the PowerPort is defectively designed and that Bard failed to adequately warn of risks associated with the implantation of the PowerPort. Bard and its Bard Access Systems subsidiary are now owned by Becton, Dickinson and Company, which is named as a defendant alongside the Bard entities in most filings.
The PowerPorts and port-a-caths are implanted under the patient’s skin and designed to deliver medication and other fluids into the patient’s bloodstream at a high flow rate. Vascular access devices like the PowerPort are most commonly implanted in cancer patients who will need frequent chemotherapy treatment over a long period.
Recent product liability lawsuits against Bard and its subsidiary, Bard Access System, Inc., allege that Bard’s PowerPort vascular access devices are susceptible to breaking, fracturing, or pinching off, increasing the risk of complications such as embolism, deep vein thrombosis (DVT), puncture of a vein, blood clots or infection.
As of the Judicial Panel on Multidistrict Litigation’s November 2, 2026 report, 4,345 product liability lawsuits are pending against Bard in the federal multidistrict litigation over injuries allegedly caused by its implantable port catheter devices. Three test trials have now reached verdicts, and a jury awarded $40 million in the first catheter fracture case.
The injury lawsuits filed in federal court were consolidated in August 2023 before the Honorable David G. Campbell, Senior United States District Judge for the District of Arizona, as MDL No. 3081, In re: Bard Implanted Port Catheter Products Liability Litigation.
Bard PowerPort Lawsuits at a Glance
- The Bard PowerPort lawsuits allege the vascular access device is defectively designed, which may lead to serious health risks.
- Individuals who allege they were harmed by Bard’s PowerPort devices are seeking compensation through individual lawsuits, not a class action. Federal cases are centralized in MDL 3081 in Arizona. New Jersey state court cases were designated a multicounty litigation in Bergen County in October 2024, and additional cases are pending in Maricopa County Superior Court in Arizona.
- PowerPort refers to several vascular access devices marketed by Bard under the PowerPort trademark, not one specific device.
- The first bellwether trial, Cook v. Becton, Dickinson and Company, was tried in Phoenix in April and May 2026. The jury returned a defense verdict on the failure to warn, failure to instruct and consumer fraud claims, but deadlocked on the central design defect claim. The plaintiff has asked for a new trial.
- In the second bellwether trial, the first catheter fracture case, a jury awarded Kimberly Divelbliss $40 million on September 4, 2026. It was the first plaintiff verdict in the MDL.
- Bard won the third bellwether trial, an infection case, in October 2026. The first blood clot trial is set to begin December 1, 2026.
- No global settlement has been announced. Any settlement figure circulating online is unverified.
The PowerPort Port-a-Cath Lawsuits
First cleared under the PowerPort name through the FDA’s 510(k) pathway in 2006, the Bard PowerPort is an implantable vascular access device that provides long-term, easy access to a patient’s vascular system so that medication and fluids can be delivered intravenously.
The Bard PowerPort lawsuits revolve around allegations that these vascular access devices manufactured by Bard have design flaws. These injury lawsuits allege that a design flaw in the catheter portion of the PowerPort can cause it to fissure, fracture, or crack and lead to a variety of serious complications for patients, particularly severe infections.
Many PowerPort catheters are made of a mixture of polyurethane and barium sulfate called ChronoFlex AL; others use silicone. The PowerPort lawsuits allege that the amount of barium sulfate can adversely affect the mechanical integrity of polyurethane, especially in high concentrations.
According to the lawsuits, Bard’s manufacturing process uses too high a concentration of barium sulfate, causing structural changes and degradation of the catheter. Eventually, these structural changes and degradation can weaken the catheter’s integrity, causing it to fracture or “pinch-off,” leading to a variety of serious injuries.
Bard PowerPort patients have filed lawsuits against C.R. Bard and Bard Access Systems after experiencing complications such as the fracture or pinching-off of the catheter, migration of the catheter, and infection, which these patients allege were due to a defect in the design of the Bard PowerPort.
If the catheter breaks or fractures, fragments can enter the blood vessels, causing potentially life-threatening conditions like:
- pulmonary embolism
- vessel perforation
- blood clots
- cardiac tamponade
- infection
Likewise, catheter migration, which occurs when the catheter moves from its original position, can cause potentially life-threatening complications such as vessel perforation, pulmonary embolism, and blood clots.
Bard PowerPort patients who suffered these complications have filed lawsuits that seek compensation against C.R. Bard and Bard Access Systems for:
- medical bills
- pain and suffering
- loss of consortium
PowerPort Lawsuits in Federal and State Courts
The litigation has grown steadily since it was centralized. The MDL held roughly 520 cases in October 2024, about 1,200 in April 2025, more than 2,500 by January 2026, 3,564 as of July 1, 2026, and 4,345 as of November 2, 2026.
Plaintiffs’ counsel have long expected the inventory to keep growing, in part because many patients never connect a port complication to the device itself. Roughly 300,000 of these ports have been implanted nationwide, and Bard has held the large majority of the market, so the filed cases still represent a fraction of the potentially affected population.
In August 2023, the U.S. Judicial Panel on Multidistrict Litigation consolidated all the federal Bard PowerPort lawsuits into MDL 3081 or In re Bard Implanted Port Catheter Products Liability Litigation and transferred all of these cases to the U.S. District Court for the District of Arizona. The cases were assigned to the Honorable David G. Campbell for pre-trial purposes. The panel entered its transfer order on August 8, 2023, and the case is docketed as 2:23-md-03081.
Where the Bard PowerPort Lawsuits Stand
Case count. The Judicial Panel on Multidistrict Litigation reported 4,345 pending lawsuits in MDL 3081 as of November 2, 2026, up from 3,564 on July 1. It remains one of the faster growing medical device dockets in the country.
A split record after three trials. Bellwether trials are test cases chosen to show how juries respond to the evidence. Each verdict shows how one jury valued one case, but together the results often shape settlement talks. So far each side has won.
First trial: mostly for Bard. Jury selection in Cook v. Becton, Dickinson and Company began April 21, 2026. The plaintiff, Robert Cook, a Minnesota rectal cancer patient, alleged that his port became infected within roughly two weeks of implantation at the Mayo Clinic, requiring surgical removal and intravenous antibiotics. His attorneys told jurors that Bard had developed safer technologies, including antimicrobial coatings and smoother catheter surfaces, as early as 2005 and repeatedly shelved them.
In May 2026 the jury found for the defense on failure to warn, failure to instruct and consumer fraud. It could not reach a unanimous verdict on whether the PowerPort was defectively designed, which is the central claim across the litigation, or on an unlawful trade practices claim. In June 2026 Cook asked for a new trial, arguing that the jury instructions were confusing and that jurors believed they were working under a deliberation deadline.
Second trial: $40 million for the plaintiff. The first catheter fracture case to reach a jury began August 18, 2026. Kimberly Divelbliss alleged that the silicone Groshong catheter on her Bard PowerPort, implanted in July 2017, fractured about two and a half years later, and that a roughly seven inch section of catheter was later found lodged in the right atrium of her heart. She needed surgery to remove it and alleged lasting heart problems that followed.
Her lawyers contended that Bard internally classified catheter fracture and embolization as a catastrophic, life threatening risk, adjusted its risk calculations in a way that avoided triggering a design change, and developed stronger catheter designs it chose not to sell. On September 4, 2026, the jury found that the catheter was defectively designed and that Bard failed to warn of the risk of fracture, and awarded Divelbliss $40 million in compensatory damages. It did not award punitive damages. It was the first plaintiff verdict in the MDL.
Third trial: for Bard. May Lattanzio, a Florida woman, alleged that the PowerPort implanted in August 2013 led to a staph bloodstream infection. The trial began in mid October, and at the end of the month the jury sided with Bard in the third bellwether trial.
Next trials. The case of Judy Hicks, a Missouri woman who alleges blood clots formed in her Bard X-Port and blocked it, is set to begin December 1, 2026. It will be the first PowerPort blood clot trial, a type of injury involved in about 30% of the cases. Lloyd Sorensen’s infection case is scheduled for February 2, 2027. Judge Campbell reduced the bellwether program from six trials to five in May 2026 after one of the selected plaintiffs, Wanda Miller, died and her family chose not to continue the case.
Key evidentiary rulings so far
- Bard cannot argue that FDA 510(k) clearance means the PowerPort was safe. The court also limited Bard’s regulatory expert, barring opinions that the design was safe, that clearance established safety, or that spoke to the FDA’s state of mind.
- Two of the plaintiffs’ interventional radiologists were permitted to testify, with the court trimming opinions about corporate intent, regulatory duties and alternative engineering designs.
- On October 26, 2026, the court denied Bard’s request to end the Hicks blood clot case before trial, sending her design defect and failure to warn claims to a jury.
Settlement posture. As of November 2026, no global settlement has been announced, and there is no settlement matrix or claims administrator. If the bellwether trials conclude without a resolution, the expected next step is remand of individual cases to their originating federal districts for trial.
Bard Port Catheter Cases in State Courts
Not every case is in the Arizona MDL. The New Jersey Supreme Court initially declined multicounty litigation designation in January 2024, citing the limited number of cases at the time. It reversed course on October 15, 2024, designating pending and future New Jersey state court cases involving Bard implanted port catheter products as a multicounty litigation and assigning them to Bergen County for centralized management. A September 2025 joint report filed in the MDL identified roughly 146 New Jersey state court cases.
A smaller group of cases, 21 as of that September 2025 report, is pending in Maricopa County Superior Court in Arizona. Because Bard is headquartered in New Jersey and the corporate conduct evidence overlaps heavily with the federal cases, the state court dockets are worth watching alongside the MDL.
AngioDynamics Port Catheter Lawsuits
Cases Consolidated in San Diego, California
In a further development, the U.S. Judicial Panel on Multidistrict Litigation has centralized all AngioDynamics port catheter lawsuits in the Southern District of California, specifically before U.S. District Judge Jinsook Ohta.
This consolidation, ordered on October 3, 2024, brings together product liability claims against AngioDynamics and its Navilyst Medical subsidiary, mirroring the approach taken with the Bard PowerPort litigation.
Key details of the AngioDynamics MDL include:
- The MDL is officially designated as MDL No. 3125, In re: AngioDynamics, Inc., and Navilyst Medical, Inc., Port Catheter Products Liability Litigation.
- At the time of consolidation, there were at least 23 lawsuits pending in 16 different district courts, with 33 additional potential actions identified in 19 districts.
- The devices at issue include the SmartPort, Vortex, Xcela and BioFlo lines.
The lawsuits allege that AngioDynamics’ port catheter devices are defective, leading to serious health risks such as:
- Device fractures
- Catheter migration
- Severe infections
- Blood clots
- Organ damage
Plaintiffs claim that these complications arise from the catheter’s manufacturing process, specifically the use of excessive barium sulfate. This excess allegedly causes the material to degrade, leading to pitting or cracking of the catheter surface.
The AngioDynamics MDL has grown considerably since consolidation. It held roughly 152 cases in May 2025, about 300 by January 2026, and 401 pending actions as of the JPML’s July 1, 2026 report. By November 2, 2026, 450 AngioDynamics cases were pending.
The AngioDynamics litigation is roughly two years behind the Bard MDL. The court entered a bellwether selection protocol in October 2025, and on August 4, 2026, each side picked nine representative cases, drawn from infection, blood clot and fracture claims. The pool is to be narrowed after early fact discovery in those cases, which is set to end in January 2027. On that schedule, a first AngioDynamics bellwether trial is unlikely before 2028.
Because the two litigations rest on the same core materials science theory, rulings and verdicts in the Bard MDL are likely to shape how the AngioDynamics cases are valued long before they reach a jury.
Implantable Port and Port a Cath Complications
Adverse Event Reports and Safety Concerns
Due to the risks medical devices may pose to patients, as well as the inability of the U.S. Food and Drug Administration to effectively evaluate medical devices for safety and efficacy, any post-release adverse events associated with a medical device must be appropriately documented and publicly reported.
This is the only means by which the FDA, physicians, and the public can identify potential defects or safety issues with a medical device. For years, adverse events reported to the FDA’s publicly accessible Manufacturer and User Facility Device Experience database (“MAUDE”) were how surveillance for potential defects and safety issues was done.
However, there are significant deficiencies in this system. Surveillance of the MAUDE database for safety issues is only effective if adverse events associated with a medical device are reported to the database accurately and timely.
Unfortunately, the reporting of adverse events to the MAUDE database is typically done by the medical device manufacturer or physicians, who are often too busy to report most adverse events to either the medical device manufacturer or MAUDE.
Compounding the inadequacies of using the MAUDE database to surveil for potential defects and safety issues with medical devices was the recent discovery that many adverse events associated with medical devices are not even placed into the publicly accessible MAUDE database.
In 2019, Kaiser Health News (now KFF) discovered that the FDA had allowed medical device manufacturers to hide adverse health events from the public via the use of the FDA’s Alternative Summary Reporting program, which permits certain medical device manufacturers, including C.R. Bard, to file adverse event reports into a non-public, internal FDA database instead of the public MAUDE database.
Established by the FDA in 1997, this program has allowed medical device manufacturers to hide millions of adverse event reports from the public. This program also allowed these manufacturers to file “summary reports” instead of individual reports for each adverse event required by the MAUDE database.
Due to public pressure, the FDA ended this secret AER database and released more than 5.7 million adverse event reports not previously known to the public.
A 2019 Kaiser Health News review of the hidden database found that a small number of device types, including surgical staplers and balloon pumps, accounted for a large share of its reports.
Bard was able to hide adverse events due to “compression or pinch-off events” in its PowerPort devices by claiming these complications were “known risks” associated with these devices or were the result of an error on the part of the surgeon in implanting these devices.
This allowed Bard to circumvent reporting these adverse events into the public MAUDE database. The discovery of the 5.7 million adverse event reports hidden from public view by the FDA and certain medical manufacturers, along with the significant number of these events associated with Bard’s PowerPort devices, helped prompt these lawsuits.
Since medical devices like the Bard PowerPort are often critical components in a patient’s treatment plan, healthcare professionals and patients need to know about potential risks and recall information.
Compared to medications and therapy, the stakes are even higher, as improperly functioning medical devices can hinder treatment efficacy, introduce new health risks, and, in severe cases, result in serious injury or death.
Being fully informed about potential safety issues associated with devices like the Bard PowerPort can empower patients and medical professionals to make informed decisions regarding their treatment options.
By staying current on safety issues and advocating for patient well-being, the community can help minimize adverse outcomes and ensure that quality care remains a priority.
Implantable PowerPort Device and Design
When treating cancer, a crucial aspect is the delivery of chemotherapy drugs. Implantable ports and catheter tubes play a significant role in ensuring patients receive medication without constant needle insertions.
A popular device for this purpose is the Bard PowerPort series of vascular access devices manufactured by C.R. Bard and its subsidiary, Bard Access Systems.
The Bard PowerPort Devices are made with various materials but are typically comprised of polyurethane or silicone for the device’s body and a mixture of polyurethane and barium sulfate for the catheter tube.
The barium sulfate is used to allow the catheter to be visible in imaging procedures so that physicians can ensure proper placement of the catheter.
However, as the Bard PowerPort lawsuits allege, the use of this barium sulfate, or at least high concentrations of it, can degrade and alter the catheter’s structural integrity, leading to fracture, breaking, or fragmentation.
These lawsuits further allege that the catheter in the Bard PowerPort devices can also migrate from its original position. The fracture, fragmenting, or migration of the catheter can also lead to a series of severe and potentially life-threatening complications.
Seeking Compensation for Injuries
If you experienced any of the following conditions post-implantation of a PowerPort device, you might be eligible for a lawsuit against the manufacturer:
- Infections: You may qualify if you suffered sepsis, septic shock, or severe infections that can lead to organ damage or death.
- Deep Vein Thrombosis (DVT): A DVT is a blood clot in a deep vein, typically in the leg. It can be life-threatening if it travels to the lungs, causing a pulmonary embolism.
- Hemorrhaging or Bleeding Injuries: Uncontrollable bleeding is a serious condition requiring immediate medical attention.
- Fluid Buildup on the Heart: Known as pericardial effusion, this can cause shortness of breath, chest pain, and other heart-related problems.
- Irregular Heartbeat: An abnormal heart rhythm known as arrhythmia can lead to serious health complications, including stroke and heart failure.
- Severe and Persistent Pain: Chronic pain, particularly in the chest or neck, could indicate a device malfunction.
- Perforations of Tissues, Vessels, and Organs: If the PowerPort catheter has punctured any tissues, vessels, or organs, this is a severe complication.
- Wrongful Death: If a loved one passed away due to any of the above complications linked to the Bard PowerPort™ device, you may be able to file a lawsuit on their behalf.
- Other Injuries: If you experienced injuries due to a fractured PowerPort catheter, you may still be eligible to file a claim.
- Catheter Fracture, Migration or Embolization: If imaging showed that your catheter broke, cracked or moved out of position, or if a fragment had to be retrieved from your heart, lungs or a blood vessel, this is the strongest documented category in the litigation. In September 2026, a jury awarded $40 million in the first fracture case to go to trial.




